Abstract
Purpose
According to the National Institute for Clinical Excellence (NICE) a risk assessment for venous thromboembolism (VTE) should be conducted on all patients undergoing elective orthopaedic surgery. We looked at the patient outcome undergoing elective Ilizarov surgery in terms of symptomatic VTE occurring during or after frame management.
Methods
We performed a retrospective chart review of all adult Ilizarov cases performed by a single surgeon between 2000–2011. Patient mortality was confirmed using the Demographics Batch Service.
Results
There were 457 cases in 445 patients with a mean age of 42.6 years (range 16–84). There were 440 lower limb and 31 upper limb frames. 185 cases were for infection and 62 cases required flap coverage by plastic surgeons. There were 31 bone transports, 112 deformity corrections, 39 lengthening, 37 fusions, 48 stabilizations and 134 compression/distractions. The mean duration of frame treatment was 34 weeks (range 6–85). According to NICE guidelines all our cases had at least one risk factor for VTE; 243 had two, 200 had three and 28 had four or more. All cases received no pharmacological VTE prophylaxis (except 14 flap cases after 2009). There were three cases of VTE in two patients (one man with deep vein thrombosis and a 17 year-old girl with two pulmonary emboli). There were 23 deaths, all unrelated to VTE. The average cost of providing VTE prophylaxis according to NICE guidelines in this group would total £89,493.40 (£195.80 per patient). If only the first 28 days of frame treatment were covered the cost would be £14,231.
Conclusion
Our reported incidence of VTE in Ilizarov surgery is low despite no pharmacological prophylaxis being used. This study challenges whether NICE guidelines are applicable to this particular group undergoing Ilizarov surgery.
